Among its phase III KEYNOTE-045 trial [104,105], 542 patients whose UC had recurred after or progressed on a platinum-based therapy were enrolled regardless of the level of PD-L1 expression and were randomly assigned to pembrolizumab (200 mg every three weeks for two years) or ICC (between paclitaxel, docetaxel, or vinflunine). The gene discussed is CD274; the disease is intrahepatic cholangiocarcinoma.